Somatic activation of KIT in distinct subtypes of melanoma.
about
Melanoma: from melanocyte to genetic alterations and clinical optionsDiagnostic role of chromosomal instability in melanomaMechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cellsAnalysis of the genome to personalize therapy for melanomaPLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cellsMelanoma genome sequencing reveals frequent PREX2 mutationsResistant mechanisms to BRAF inhibitors in melanomaReceptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cellsSomatic DNA mutation analysis in targeted therapy of solid tumoursChinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Updates in Therapy for Advanced MelanomaMelanoma: oncogenic drivers and the immune systemMelanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradoxClinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challengesThe GIST of targeted therapy for malignant melanomaStructural and functional properties of platelet-derived growth factor and stem cell factor receptorsMelanoma: new insights and new therapiesPathways and therapeutic targets in melanomaProgression of cutaneous melanoma: implications for treatmentEmerging phytochemicals for prevention of melanoma invasionMelanoma: from mutations to medicineActivity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanomaNRAS mutation status is an independent prognostic factor in metastatic melanoma.Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinRecurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapyTERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.Cutaneous Melanoma in AsiansSomatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxinHotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivityRoutine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trialsA melanoma molecular disease modelBRAF mutations in advanced cancers: clinical characteristics and outcomesColocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escapeFunction and Clinical Implications of Long Non-Coding RNAs in Melanoma.MERTK receptor tyrosine kinase is a therapeutic target in melanoma.Discrepant alterations in main candidate genes among multiple primary melanomasIn-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma.Improving melanoma classification by integrating genetic and morphologic featuresNoncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study
P2860
Q21284811-0A36DA14-A69E-48C2-8D18-1486C6E86FBDQ21285151-30A084C8-D73D-4440-AE50-32E2D8BA31E3Q24313261-26670FBF-593D-4E04-A176-91E5DCECEA5CQ24601008-93D232F2-5606-4820-8DCB-DC088ADF94FCQ24606438-A854745B-B148-4C59-9F06-DF5E0B753B85Q24610463-C6863E04-3588-40BE-9369-1AB506414750Q26739717-D5C543B1-6A63-4F2A-ADDB-9D979A089C8AQ26740953-8625B857-628C-4354-982F-F0EB3BDB6BB5Q26770324-6D43C741-7477-4E3D-8B6C-53CF59EF8F8CQ26770492-3A0797F7-AAAB-4D3A-9B48-5CB3D5BABD3AQ26771119-DFCD6582-AF48-4DE2-8EB5-46F6345C7135Q26775598-0CD38D7E-AEA0-4115-894F-2A3FAC3AB709Q26783118-02E8F804-8B41-4F72-A802-3408034F4FAEQ26823978-665934F3-B65E-4EB7-905C-0090C5DD8A21Q26827092-C3B4961E-35EC-4B57-994C-5A1AA2F3326AQ26829546-BBC23E06-B937-4C52-9AD7-649C40114F01Q26853127-C8501C2A-150B-4F48-82D9-0DF42BBCBD90Q26865736-3D214E7A-A66A-4927-A52E-A3A61241ACDCQ27001734-179E9965-1953-45E9-BB7D-53BF9F110B88Q27023283-7FBE68FD-D90A-436B-AE7E-0528C1727C93Q27024061-1EAE3E93-8D70-427F-9468-26CF70E80AD0Q27851482-F9D164CB-FCB8-412C-A61B-684217E010CDQ27851611-9408F8F9-85C9-451E-B949-D052A967786BQ27851695-E9496638-B08C-4574-BF13-DB0F08AF19A0Q27852360-FAC831BB-C34B-4628-A685-FD04F2273681Q27852482-AA5033FB-4ADC-4539-8AC3-68C0F0DE625CQ27853068-7DDB3B36-3005-4858-9DCB-662E186EC2D4Q28078576-D6745BFF-18B2-48D3-A832-563FE44E9251Q28397328-0D742977-70C9-480F-93A8-8333AF63CF54Q28541374-55CD2501-99EA-4AE3-812B-3665E16C97DAQ28730438-CD7A361D-F376-41FA-AE01-303BA3C1D175Q28741507-E8D8110C-ED31-40FD-A7A6-482AF19F4B4EQ28743591-724E3F67-36F1-4DAB-8966-C9367B577473Q29620881-442E534E-C44C-4366-A2D9-DB8396924525Q30313298-DF9E2025-F40E-4902-92D8-17BC9851F7E7Q30539324-712466AC-FDE0-4B6A-B460-D7BBAE1FFD82Q30578299-C709B135-A866-4DA6-92FF-C0BD9FDDC6CEQ30936571-CA69998E-2F49-498C-AEEF-3F854AF58504Q33340639-91AA71E2-10D4-4531-BB6C-C653A6174A43Q33567330-F51A5E4C-DE5C-4D0E-BBF6-09D043925B4C
P2860
Somatic activation of KIT in distinct subtypes of melanoma.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Somatic activation of KIT in distinct subtypes of melanoma.
@ast
Somatic activation of KIT in distinct subtypes of melanoma.
@en
Somatic activation of KIT in distinct subtypes of melanoma.
@nl
type
label
Somatic activation of KIT in distinct subtypes of melanoma.
@ast
Somatic activation of KIT in distinct subtypes of melanoma.
@en
Somatic activation of KIT in distinct subtypes of melanoma.
@nl
prefLabel
Somatic activation of KIT in distinct subtypes of melanoma.
@ast
Somatic activation of KIT in distinct subtypes of melanoma.
@en
Somatic activation of KIT in distinct subtypes of melanoma.
@nl
P2093
P356
P1476
Somatic activation of KIT in distinct subtypes of melanoma.
@en
P2093
Boris C Bastian
Daniel Pinkel
Klaus Busam
P304
P356
10.1200/JCO.2006.06.2984
P407
P577
2006-08-14T00:00:00Z